Hostname: page-component-77c89778f8-vpsfw Total loading time: 0 Render date: 2024-07-18T22:04:51.907Z Has data issue: false hasContentIssue false
  • English
  • Français

Axial Improvement after Casirivimab/Imdevimab Treatment for COVID-19 in Parkinson’s Disease

Published online by Cambridge University Press:  29 June 2022

Valentina Fioravanti ,
Francesco Cavallieri Open the ORCID record for Francesco Cavallieri [Opens in a new window] ,
Alessio Di Fonzo ,
Giulia Toschi ,
Sara Grisanti ,
Gaetano Salomone ,
Mario Zappia  and
Franco Valzania
Valentina Fioravanti
Affiliation:
Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Francesco Cavallieri*
Affiliation:
Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena and Reggio Emilia, Italy
Alessio Di Fonzo
Affiliation:
IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Neurology Unit, Milan, Italy
Giulia Toschi
Affiliation:
Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Sara Grisanti
Affiliation:
Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena and Reggio Emilia, Italy
Gaetano Salomone
Affiliation:
Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Mario Zappia
Affiliation:
Department of Medical and Surgical Sciences and Advanced Technologies “G.F. Ingrassia”, Neuroscience Section, University of Catania, Catania, Italy
Franco Valzania
Affiliation:
Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
*
Corresponding author: Francesco Cavallieri, Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123, Reggio Emilia, Italy. Email: Francesco.Cavallieri@ausl.re.it
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

CoronavirusCOVID-19Monoclonal antibodiesParkinson’s diseaseSARS-CoV-2
Type
Letter to the Editor: New Observation
Information
Canadian Journal of Neurological Sciences , Volume 50 , Issue 5 , September 2023 , pp. 777 - 778
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Valentina Fioravanti and Francesco Cavallieri equally contributed to the manuscript.

References

Weinreich, DM, Sivapalasingam, S, Norton, T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384:238–51.CrossRefGoogle ScholarPubMed
Cavallieri, F, Budriesi, C, Gessani, A, et al. Dopaminergic treatment effects on dysarthric speech: acoustic analysis in a cohort of patients with advanced Parkinson’s disease. Front Neurol. 2021;11:616062.CrossRefGoogle Scholar
Bohnen, NI, Yarnall, AJ, Weil, RS, et al. Cholinergic system changes in Parkinson’s disease: emerging therapeutic approaches. Lancet Neurol. 2022;21:381–92.CrossRefGoogle ScholarPubMed
Kopańska, M, Batoryna, M, Bartman, P, Szczygielski, J, Banaś-Ząbczyk, A. Disorders of the cholinergic system in COVID-19 Era-A review of the latest research. Int J Mol Sci. 2022;23:672.CrossRefGoogle ScholarPubMed
Oliveira, ASF, Ibarra, AA, Bermudez, I, et al. A potential interaction between the SARS-CoV-2 spike protein and nicotinic acetylcholine receptors. Biophys J. 2021;120:983–93.CrossRefGoogle ScholarPubMed
Bouali-Benazzouz, R, Benazzouz, A. Covid-19 infection and Parkinsonism: is there a link? Mov Disord. 2021;36:1737–43.CrossRefGoogle ScholarPubMed
Cavallieri, F, Fioravanti, V, Toschi, G, et al. COVID-19 and Parkinson’s disease: a casual association or a possible second hit in neurodegeneration? J Neurol. 2021;1-3.Google Scholar
Jaiswal, V, Alquraish, D, Sarfraz, Z, et al. The influence of coronavirus disease-2019 (COVID-19) on Parkinson’s disease: an updated systematic review. J Prim Care Community Health. 2021;12:21501327211039709.CrossRefGoogle ScholarPubMed
Sinha, S, Mittal, S, Roy, R. Parkinson’s disease and the COVID-19 pandemic: a review article on the association between SARS-CoV-2 and α-synucleinopathy. J Mov Disord. 2021;14:184–92.CrossRefGoogle ScholarPubMed
Udovin, L, Otero-Losada, M, Bordet, S, et al. Effects of angiotensin type 1 receptor antagonists on Parkinson’s disease progression: an exploratory study in the PPMI database. Parkinsonism Relat Disord. 2021;86:34–7.CrossRefGoogle ScholarPubMed
Reardon, KA, Mendelsohn, FA, Chai, SY, Horne, MK. The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson’s disease. Aust N Z J Med. 2000;30:48–53.CrossRefGoogle ScholarPubMed
Contaldi, E, Magistrelli, L, Milner, AV, Cosentino, M, Marino, F, Comi, C. Potential protective role of ACE-inhibitors and AT1 receptor blockers against levodopa-induced dyskinesias: a retrospective case-control study. Neural Regen Res. 2021;16:2475–8.CrossRefGoogle ScholarPubMed
https://www.ema.europa.eu/en/documents/referral/regn-cov2-antibody-combination-casirivimab/imdevimab-covid19-article-53-procedure-assessment-report_en.pdf.Google Scholar

Fioravanti et al. supplementary material

Fioravanti et al. supplementary material

Download Fioravanti et al. supplementary material(Video)
Video 10.6 MB